Oak Associates’s Bio-Rad Laboratories Class A BIO Stock Holding History

Oak Associates’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,107	Closed	-$1M	–	132
2025 Q1	$1M	Hold	4,107	–	–	0.08%	100
2024 Q4	$1.35M	Hold	4,107	–	–	0.09%	95
2024 Q3	$1.37M	Hold	4,107	–	–	0.09%	91
2024 Q2	$1.12M	Hold	4,107	–	–	0.07%	99
2024 Q1	$1.42M	Buy	+4,107	New	+$1.35M	0.1%	94
2023 Q4	–	Sell	-4,489	Closed	-$1.61M	–	132
2023 Q3	$1.61M	Sell	4,489 -401	-8%	-$155K	0.13%	83
2023 Q2	$1.85M	Hold	4,890	–	–	0.15%	80
2023 Q1	$2.34M	Buy	+4,890	New	+$2.29M	0.19%	74
2022 Q4	–	Sell	-3,679	Closed	-$1.53M	–	144
2022 Q3	$1.53M	Buy	3,679 +1,121	+44%	+$559K	0.13%	85
2022 Q2	$1.27M	Buy	+2,558	New	+$1.33M	0.1%	92

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

FPA

First Pacific Advisors El Segundo, California $8.09B AUM 21.95% 1-Year Est. Return

Oak Associates's BIO Position: Q2 2025 in Review

Oak Associates sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2025, closing a stake of 4,107 shares — an estimated $1M sold.

Oak Associates first reported a position in BIO in Q2 2022 and held it in 10 quarters. The position peaked at $2.34M in Q1 2023. 384 funds tracked by Wall St. Rank hold BIO as of Q2 2025.

Oak Associates reported no remaining Bio-Rad Laboratories Class A position as of Q2 2025 after selling out during the quarter.
Oak Associates sold 4,107 Bio-Rad Laboratories Class A shares in Q2 2025, an estimated $1M.
Oak Associates first reported a position in Bio-Rad Laboratories Class A in Q2 2022 and held it in 10 quarters.
Oak Associates's Bio-Rad Laboratories Class A position peaked at $2.34M in Q1 2023.
384 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2025.

Based on Oak Associates's 13F filing for Q2 2025, filed 12 Aug 2025.